TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lyra Therapeutics ( (LYRA) ) has provided an update.
On August 1, 2025, Lyra Therapeutics announced the immediate termination of Dr. Harlan W. Waksal’s employment as Executive Chairman, following a mutual agreement. Dr. Waksal also resigned from the Board of Directors, and Maria Palasis, the company’s President and CEO, was appointed as the new Chair of the Board, while Jim Tobin continues as Lead Independent Director.
The most recent analyst rating on (LYRA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.
Spark’s Take on LYRA Stock
According to Spark, TipRanks’ AI Analyst, LYRA is a Neutral.
Lyra Therapeutics’ overall stock score reflects significant financial struggles and weak technical indicators. However, recent corporate achievements and strategic plans offer some optimism for future growth, notably in the biotechnology sector’s volatile environment.
To see Spark’s full report on LYRA stock, click here.
More about Lyra Therapeutics
Lyra Therapeutics operates in the biotechnology industry, focusing on developing therapies for ear, nose, and throat diseases. The company is known for its innovative drug delivery systems and aims to address unmet medical needs in this specialized market.
Average Trading Volume: 696,986
Technical Sentiment Signal: Sell
Current Market Cap: $10.71M
See more data about LYRA stock on TipRanks’ Stock Analysis page.